Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pediococcus acidilactici TCI188
- Development stage
- Preclinical
- Lead developer
- TCI
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Pediococcus acidilactici TCI188 is a proprietary probiotic strain developed by TCI Co., Ltd. (Triple Climax Inc.), a leading Taiwanese manufacturer of functional foods and dietary supplements. This specific strain of lactic acid bacteria was isolated and characterized for its potential metabolic benefits, particularly in the context of weight management and body fat reduction. TCI188 is thought to exert its effects by modulating the gut microbiome, which in turn influences host lipid metabolism and inhibits adipogenesis. Preclinical and clinical evaluations sponsored by the developer have suggested that the strain can help reduce body weight, body fat percentage, and waist circumference. As a live biotherapeutic ingredient, it is utilized in various consumer health products, including probiotic powders, capsules, and functional beverages, aimed at individuals seeking metabolic health support.
- Brand names
- TCI188TCI-188TCI 188
- Other names
- Pediococcus acidilactici TCI188P. acidilactici TCI188
Beyond the preview
Go deeper on Pediococcus acidilactici TCI188.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pediococcus acidilactici TCI188.